Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA as First-Line Treatment for Adult Patients With Advanced RCC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. AMC
4. MSFT
5. ACN
6. FFAI
7. PAGP
8. WBD
9. FAN
10. COHR

Go back to Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA as First-Line Treatment for Adult Patients With Advanced RCC
Merck & Co. (NYSE: MRK) Delayed: 146.87 --0 (-0%)
Previous Close $146.87    52 Week High $65.46 
Open $146.87    52 Week Low $47.97 
Day High $146.87    P/E 99.91 
Day Low $146.87    EPS $1.47 
Volume 10,842